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معرفة وسلوك املرضى جتاه املشاركة يف التجارب السريرية يف عمان
دراسة مقطعية
ح�سني علي اللواتي، خالد البيماين، مهرة الزدجايل، ن�رصة العبيداين، زيانة الكيومي، مرت�سى خمي�ض اخلابوري
abstract: Objectives: Clinical trials are prospective studies on human subjects designed to answer various 
clinical questions. However, only a limited number of clinical trials have been conducted in Oman. This study 
aimed to assess the knowledge and attitudes of Omani patients and their relatives towards participating in clinical 
trials. Methods: This cross-sectional study was conducted between October 2015 and March 2016 among 174 
patients and relatives attending the Haematology and Oncology Outpatient Clinics and Day Care Unit of the 
Sultan Qaboos University Hospital, Muscat, Oman. A self-administered questionnaire was designed to elicit 
participants’ knowledge of and attitudes towards participation in clinical trials. Results: A total of 100 patients and 
relatives agreed to take part in the study (response rate: 57.5%). The male-to-female ratio was 1:1.2. Only 31.3% of 
the studied population knew what clinical trials were and only 6.5% had themselves previously participated in a 
clinical trial. The majority agreed or strongly agreed that they would participate in clinical trials related to their own 
condition (59.2%). Overall, 89.7% expected to be informed about potential clinical trials by their treating physicians. 
Conclusion: Omanis had a low level of knowledge of clinical trials and a very low rate of previous participation 
in such trials, despite a moderate level of interest. Patients should therefore be educated and informed of ongoing 
clinical trials in order to improve participation rates for clinical trials conducted in Oman.
Keywords: Attitudes; Knowledge; Clinical Trials as Topic; Patient Participation; Oman.
امللخ�ص: الهدف: التجارب ال�رصيرية هي درا�سات مرتقبة م�ستقبلية على الب�رص م�سممة لالإجابة على اأ�سئلة خمتلفة تخ�ض الطب ال�رصيري، 
بالرغم من ذلك، هناك ندرة يف التجارب ال�رصيرية التي اأجريت يف عمان. هدفت هذه الدرا�سة اإىل تقييم معرفة و�سلوك املر�سى العمانيني 
 174 2016 من بني  2015 و مار�ض  واأقاربهم جتاه امل�ساركة يف التجارب ال�رصيرية. الطريقة: اأجريت هذه الدرا�سة املقطعية بني اأكتوبر 
من املر�سى واأقاربهم الذين ح�رصوا عيادات اأمرا�ض الدم واالأورام ووحدة الرعاية النهارية مب�ست�سفى جامعة ال�سلطان قابو�ض يف م�سقط 
ال�رصيرية.  التجارب  امل�ساركة يف  امل�ساركني وموقفهم جتاه  تتعلق مب�ستوى معرفة  بيانات  ا�ستبيان ال�ستخال�ض  يف عمان، مت ت�سميم 
النتائج: وافق ما جمموعه 100 مري�ض اأواأقارب مر�سى على امل�ساركة يف الدرا�سة )معدل اال�ستجابة: %57.5(. وكانت ن�سبة الذكور اإىل 
االإناث 1:1.2. اأظهرت النتائج باأن %31.3 من امل�ساركني لديهم معرفة م�سبقة عن التجارب ال�رصيرية و %6.5 فقط كانوا قد �ساركوا �سابقًا 
يف جتربة �رصيرية. وافق االأغلبية على اأنهم �سي�ساركون يف التجارب ال�رصيرية املتعلقة بحالتهم اخلا�سة )%59.2(، و %89.7 توقعوا باأن 
املعرفة  من  منخف�ض  م�ستوى  العمانيني  لدى  كان  اخلال�صة:  املعاجلني.  االأطباء  قبل  من  حمتملة  �رصيرية  جتربة  باأي  علم  على  يكونوا 
بالتجارب ال�رصيرية ومعدل منخف�ض جداً من امل�ساركة ال�سابقة يف مثل هذه التجارب، بالرغم من وجود م�ستوى معتدل من االإهتمام. 
لذلك ينبغي تثقيف املر�سى واطالعهم على التجارب ال�رصيرية اجلارية من اأجل حت�سني معدالت امل�ساركة للتجارب ال�رصيرية يف عمان.
الكلمات املفتاحية: �سلوك؛ املعرفة؛ التجارب ال�رصيرية كمو�سوع؛ م�ساركة املر�سى؛ عمان.
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Advances in Knowledge
- Omani patients and their relatives were found to have low levels of knowledge of clinical trials; however, there was a moderate level of 
interest in participating. 
Application to Patient Care 
- Making patients aware of clinical trials is likely to improve their knowledge of and participation in such trials. Based on the findings 
of this study, physicians in Oman should be encouraged to discuss the option of participating in clinical trials with patients when 
suitable. Moreover, information about ongoing clinical trials should be made accessible to patients at different hospitals.
doi: 10.18295/squmj.2018.18.01.009
A clinical trial is a prospective study of human subjects in which the effect of one or more interventions is compared with a control group in order to answer important clinical questions.1 It is a major type of investigative research methodology that assesses new interventions in order 
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to provide non-biased insight into their effectiveness, 
as well as their potential adverse events and comp-
lications. The results of clinical trials are considered to 
constitute high-quality evidence in clinical medicine 
and have contributed to vast improvements in the 
quality of healthcare provision in various fields.2–4 
However, according to the clinical trial registry of the 
National Library of Medicine (Bethesda, Maryland, 
USA), only 20 registered clinical trials to date have 
involved Oman, most of which were sponsored by 
various pharmaceutical companies.5 
While patients’ attitudes towards participating in 
clinical trials have been analysed in other areas of the 
world, they have not yet been studied in Oman; as such, 
the reasons underlying low clinical trial participation 
among the local population remain unclear.6–8 Various 
personal, sociocultural or religious factors may cause 
patients to be reluctant to participate in clinical trials. 
In addition, inadequate knowledge about clinical trials 
among patients, relatives and physicians, a lack of local 
expertise or previous experience in running clinical 
trials and limited funding, support and infrastructure 
may all act as barriers to participation.1 Accordingly, in 
order to improve the status of clinical trials in Oman, it 
is important to understand patients’ attitudes towards 
participation in such trials so as to identify areas for 
improvement. This study therefore aimed to assess the 
knowledge and attitudes of Omani patients and their 
relatives towards participating in clinical trials.
Methods
This cross-sectional study was conducted at the Sultan 
Qaboos University Hospital (SQUH), Muscat, Oman, 
between October 2015 and March 2016. A total of 174 
adult patients and their relatives visiting the SQUH 
Haematology and Oncology Outpatient Clinics and the 
Day Care Unit were invited to participate in the study. 
Patients were excluded from the study if they refused to 
participate or were too sick to fill out the questionnaire. 
Based on assumptions of 10% accuracy and using a 95% 
confidence interval with a convenient sampling strategy, 
a minimum sample of 97 participants was deemed 
necessary.9 However, given the potential for missing data, 
the target sample size was increased to 100 partic-
ipants.
A 48-item questionnaire to determine  knowledge 
of and attitudes towards participating in clinical 
trials was designed based on an extensive literature 
review of questionnaires covering similar topics. New 
items were added and existing items were modified 
in order to conform to the local culture in Oman. 
The final version of the questionnaire included three 
domains. The first 11-item domain served to elicit 
sociodemographic information about the subjects, 
including age, gender and disease characteristics. The 
second 14-item domain assessed participants’ know-
ledge of clinical trials, with participants answering 
either “yes”, “no” or “not applicable” to each question. 
The third 23-item domain consisted of a number of 
statements with which the participants were asked 
to rate their level of agreement. This domain covered 
various topics which might impact a participant’s 
willingness to participate in a clinical trial, such as the 
blinded nature of a clinical trial, the random allocation 
of participants to intervention and control groups 
during the clinical trial, potential side-effects of the 
treatment used in the clinical trial and other factors 
influencing the decision-making process for clinical 
trial participation. Each item was scored on a five-
point Likert scale using the responses “strongly agree”, 
“agree”, “neutral”, “disagree” or “strongly disagree”. All 
responses to the questionnaire were self-assessed by 
the participants, without the aid of physicians or nurses.
During the design of the questionnaire, an exten- 
sive literature review was performed to ensure that all 
areas related to the topic of clinical trial participation 
were included. Subsequently, an expert assessed the 
face validity of the content and design of the quest-
ionnaire. The items included in the survey were found 
to reasonably cover all important areas of assessment. 
The questionnaire was translated into Arabic and 
back-translated to English to ensure the semantic equi-
valence of the Arabic version.10 In order to remove any 
ambiguous items, the questionnaire was pilot-tested 
on 10 medical students and five of the participants 
of the full study. The reliability of all items in the second 
and third domains of the questionnaire was assessed 
using Cronbach’s alpha (0.944).
Data were analysed using the Statistical Package 
for the Social Sciences (SPSS), Version 22.0 (IBM Corp, 
Armonk, New York, USA). Continuous variables were 
presented as means and standard deviations or medians 
and ranges, as appropriate. Categorical variables were 
presented as frequencies and percentages.
Ethical approval for this study was obtained from 
the Medical Research & Ethics Committee of the 
College of Medicine & Health Sciences, Sultan Qaboos 
University (MREC #1178).
Results
A total of 100 subjects agreed to participate in the 
study, with the remaining 74 declining due to time 
limitations or an inability to read and write (response 
rate: 57.5%). The mean age of the participants was 
36 years (range: 17–71 years old) and the male-to-
female ratio was approximately equal (1:1.2). Most of 
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the participants were patients (70%) and resided in 
Muscat or Ad Dakhiliyah (27% and 20%, respectively). 
Their travel time varied, with 38% travelling less than 
one hour and 35% travelling more than two hours to 
arrive at SQUH. The majority of patients had been 
educated to a high school level or higher (81%). 
Approximately half of the participants had a monthly 
income of less than 1,000 Omani riyals per month 
(51%). The majority of the participants suffered from 
a chronic condition (54%), most of which were related 
to the medical subspecialties of oncology (51%) or 
haematology (34%) [Table 1].
In terms of their knowledge regarding clinical 
trials, only 31.3% and 31.6% of the participants knew 
what clinical trials were and why they were conducted. 
Very few of the participants had previously participated 
in clinical trials (6.5%). Just under a third of the 
patients knew that clinical trials were experiments 
on human subjects (32.6%). Few of the participants 
thought that there was risk involved in clinical trial 
participation (16.3%). Of the participants, 66.3% knew 
that clinical trials were ethical, 70.5% were aware that 
clinical trials were beneficial to society and 71.4% knew 
that clinical trials were critical for the advancement of 
medical care and knowledge. Most of the participants 
(66.7%) thought that the Omani government should 
allow pharmaceutical companies to conduct clinical 
trials, with 62.3% aware that such companies would 
require governmental approval prior to conducting a 
trial. Many participants (33.7%) had found out about 
clinical trials from their medical care professionals, 
whereas 32.9% had read about them on the Internet. 
Mass media and other patients were the least frequent 
sources of information about clinical trials (31% and 
14.9% of participants, respectively) [Table 2]. 
With regards to their attitudes towards and 
willingness to participate in clinical trials, 59.2% of 
the participants either agreed or strongly agreed that 
they would participate in clinical trials related to their 
Table 1: Sociodemographic characteristics of patients 
and relatives visiting the Sultan Qaboos University 
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condition. Most patients either agreed or strongly 
agreed that they would not mind being contacted 
regarding clinical trials by phone (57.3%) or e-mail 
(42.7%). Of the participants, 38.5% either agreed or 
strongly agreed that they did not mind the randomised 
nature of allocation to a study group in a clinical trial, 
while 33.4% of the cohort either agreed or strongly 
agreed that they did not mind participating in a blinded 
trial. However, 32.1% were unsure if they would partic-
ipate in a clinical trial if the treatment involved had 
potential side-effects. Nevertheless, the majority of the 
participants either agreed or strongly agreed that they 
would want to be informed of the results of the clinical 
trial in which they had participated (84.6%). 
The vast majority of participants either agreed 
or strongly agreed that they expected to be informed 
by their doctors about ongoing clinical trials related 
to their medical condition (89.7%). Moreover, most 
participants agreed or strongly agreed that clinical trials 
conducted at SQUH would likely follow both safety 
(86.1%) and privacy (79.5%) precautions. However, 
47.7% of participants either agreed or strongly agreed 
that clinical trials sponsored by pharmaceutical compa- 
nies were likely to result in a conflict of interest. More 
than half of participants either agreed or strongly 
agreed that most current treatments in medicine 
were based on evidence from clinical trials (53.5%). 
Just over half of the participants indicated that they 
would involve a family member in their decision as to 
whether to participate in a clinical trial (50.6%). 
Factors which positively influenced willingness to 
participate in a clinical trial included recommendations 
by a treating physician (61.2%) and the ineffectiveness 
of current therapy (59.3%). Just under half of the partic-
ipants indicated that a negative perception of clinical 
trials would not alter their decision to participate in a 
trial (49.4%). Similarly, 44.1% either agreed or strongly 
agreed that the unconfirmed nature of treatment in 
a clinical trial would not affect their decision to parti-
cipate. Lastly, 14% strongly agreed and 45.3% agreed 
that they would be more likely to participate in clini-
cal trials focusing on complementary or alternative 
medicine [Table 3].
Discussion
The results of the current study revealed that most 
Omani patients and their relatives had a low level 
of knowledge about clinical trials. This finding was 
to be expected, given the generally low number of 
clinical trials conducted in Oman.5 Other countries 
in the region have reported a low level of knowledge 
and awareness concerning clinical trials in similar 
populations.11 A study from India also reported that 
only 40.2% of participants knew what clinical trials 
were.12 Local awareness of clinical trials and the 
rationale for such research can be improved, potentially 
leading to higher rates of participation. To this end, 
patients in Oman should be kept informed of ongoing 
clinical trials, perhaps via posted advertisements in 
local hospitals and on social media platforms. 
In the current study, a very low proportion of the 
surveyed patients and relatives had previously been 
enrolled in clinical trials. Nair et al. observed that only 
0.5% of all clinical trials conducted worldwide included 
participants from the Middle East and North Africa.13 
This finding is discouraging and may reflect various 
barriers to clinical trial participation in the region, such 
as poor infrastructure, low expertise, lack of funding 
and patient reluctance. Nevertheless, the majority of 
participants in the present study believed that clinical 
trials were beneficial to society; this is consistent 
with findings from Balasubramanian et al.’s study, in 
Table 2: Knowledge of clinical trials among patients and 
relatives visiting the Sultan Qaboos University Hospital, 
Muscat, Oman (N = 100)
Questionnaire item Percentage
Yes No
Do you know what clinical trials are? 31.3 68.7
Do you know why clinical trials are 
conducted?
31.6 68.4
Have you participated in clinical trials 
before?
6.5 93.5
Is a clinical trial an experiment on 
humans?
32.6 67.4
Do you think that clinical trials benefit 
society?
70.5 29.5
Are clinical trials ethical to conduct? 66.3 33.7
Is there risk involved in participating in 
a clinical trial?
16.3 83.7
Is it necessary for a company to get 
approval from the government to 
conduct a clinical trial?
62.3 37.7
Are clinical trials critical to advance 
medicine and improve therapy 
effectiveness?
71.4 28.6
Should pharmaceutical companies be 
allowed to conduct clinical trials in 
Oman?
66.7 33.3
Did you find out about clinical 
trials from physicians or medical 
professionals?
33.7 66.3
Did you find out about clinical trials 
from mass media?
31 69
Did you find out about clinical trials 
from the Internet?
32.9 67.1
Did you find out about clinical trials 
from other patients?
14.9 85.1
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Table 3: Attitude towards clinical trials among patients and relatives visiting the Sultan Qaboos University Hospital, Muscat, 
Oman (N = 100)
Item Percentage
Strongly agree Agree Neutral Disagree Strongly disagree
I would be interested in participating in clinical trials 
related to my medical condition
18.1 41.1 32.5 7.2 1.2
I find it appropriate for an investigator to contact me by 
phone to inform me of a research project
6.1 51.2 14.6 26.8 1.2
I find it appropriate for an investigator to contact me by 
e-mail to inform me of a research project
4.9 37.8 24.4 28 4.9
I find it acceptable to be allocated in a random fashion to 
receive either treatment or a placebo during a clinical trial 
9.6 28.9 21.7 26.5 13.3
I find it acceptable to participate in a blinded clinical trial, 
knowing that both the participants and physicians often 
have no knowledge of which treatment arm the patient 
will be allocated to
2.5 30.9 29.6 25.9 11.1
Even if I was told that the treatment prescribed to me in 
a clinical trial had potential side-effects, I would still be 
interested in participating
8.3 27.4 32.1 22.6 9.5
It is important for me to be informed by the investigator 
about the results of the clinical trial in which I participated
31 53.6 11.9 2.4 1.2
I expect my treating physician to inform me about current 
clinical trials involving medical conditions related to me
41.4 48.3 5.7 3.4 1.1
All reasonable precautions to ensure my safety are likely to 
be taken in clinical trials conducted at SQUH
32.6 53.5 10.5 2.3 1.2
All reasonable precautions to protect my privacy are likely 
to be taken in clinical trials conducted at SQUH
36.1 43.4 15.7 3.6 1.2
Clinical trials sponsored by pharmaceutical companies are 
likely to have conflicts of interest
16.7 31 42.9 4.8 4.8
Most current medical treatments are based on evidence 
from clinical trials
7 46.5 36 8.1 2.3
I would not involve anyone else in my decision to 
participate in a clinical trial
4.8 27.7 30.1 27.7 9.6
I would ask my children/spouse/parents before I 
participated in a clinical trial
9.6 41 22.9 18.1 8.4
The availability of a new medical treatment not available 
outside of a clinical trial would influence my decision to 
participate in the trial
12.5 32.5 36.3 15 3.8
The idea of contributing to medical knowledge would 
influence my decision to participate in a clinical trial
8.4 37.3 32.5 18.1 3.6
I would participate in a clinical trial if my doctor 
recommended it to me
18.8 42.4 24.7 12.9 1.2
I would be more likely to participate in clinical trials if I 
was not benefitting from my current treatment
15.1 44.2 23.3 14 3.5
A negative perception of clinical trials would not influence 
my decision to participate in a trial
9.2 40.2 33.3 14.9 2.3
The unconfirmed nature of treatment would not influence 
my decision to participate in a clinical trial
4.8 39.3 32.1 20.2 3.6
The thought of having to come to hospital frequently 
would not influence my decision to participate in a clinical 
trial
8.2 37.6 30.6 18.8 4.7
Preferring standard treatment would not influence my 
decision to participate in a clinical trial
10.6 38.8 37.6 11.8 1.2
I would be more likely to participate in clinical trials if they 
focused on complementary/alternative medicine
14 45.3 25.6 12.8 2.3
SQUH = Sultan Qaboos University Hospital.
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which the same sentiment was echoed by 54.5% of 
Indian patients.12 Not unexpectedly, most participants 
agreed that clinical trials were ethical and that clinical 
trials conducted at SQUH (i.e. in a university hospital 
setting) would conform to necessary safety and privacy 
standards. A recent study from Saudi Arabia found 
that 48.7% of respondents believed clinical trials were 
conducted in an ethical manner.11
A low percentage of participants in the current 
study believed that there was risk involved in partic-
ipating in clinical trials. In comparison, 48.71% of 
Indian participants in Balasubramanian et al.’s study 
considered clinical trial participation to be risky.12 
The reason for this difference in results is unclear, 
especially as the level of knowledge of clinical trials in 
both cohorts was poor. Despite the potential risk of 
adverse events or side-effects, over one-third of the 
Omani participants in the present study reported that 
they would still be inclined to participate in a clinical 
trial. This finding could potentially be explained by 
expectations that clinical trial protocols would undergo 
rigorous review by various regulatory committees in 
order to ensure the participants’ safety. 
For the majority of patients worldwide, their main 
point of reference regarding medical treatments is 
their treating or family physician. In the present 
study, most participants were made aware of clinical 
trials by their treating physicians; moreover, the vast 
majority expected to be informed of relevant ongoing 
clinical trials by their physician and to be updated 
regarding the results of any clinical trials in which 
they had participated. A Korean study reported that 
52% of oncology patients were informed of available 
clinical trials by their treating physicians and that 
26.8% were willing to participate in clinical trials if 
such participation was recommended by their treating 
physician.14 In a study from the Mayo Clinic in the 
USA, most participants indicated that they expected 
their treating physician to inform them about ongoing 
clinical trials as a treatment option and that they would 
not be willing to participate in future clinical trials if 
the results of previous trials had not been disclosed 
to them.6 
 As is to be expected given the local culture, 
approximately half of the Omani participants in 
the present study were in favour of involving their 
family members when making decisions regarding 
their participation in clinical trials. In contrast, Lee 
et al. reported that only 24.1% of Korean participants 
would involve their family members before agreeing 
to enrol in a clinical trial.14 In the current study, the 
availability of a new treatment not available outside of 
a clinical trial was a strong influencing factor when it 
came to choosing to enrol in a  clinical trial. This is 
generally considered to be one of the major benefits of 
clinical trial enrolment. As reported by Madsen et al., 
access to a new drug or diagnostic tool and a desire for 
enhanced monitoring are major influencing factors for 
clinical trial participation.7
This study had a number of strengths. To the 
best of the authors’ knowledge, this is the first survey 
detailing the knowledge of and attitudes towards 
clinical trials among a cohort of Omani patients and 
relatives. Moreover, although the sample was small, 
the findings of this study could be used as a basis 
to further develop the questionnaire and to carry 
out more extensive surveys on this topic. Finally, as 
the study sample included participants from both 
haematology and oncology outpatient departments, 
the responses are likely homogeneous.
Nevertheless, the results of this study should be 
interpreted in the light of certain limitations. According 
to previous research, only 6% of eligible participants 
choose to enrol in clinical trials.15 In the researchers’ 
personal experience, the majority of Omani patients 
who are invited to enrol in an actual clinical trial 
refuse to participate. As such, the favourable responses 
observed in the current study are likely attributable to 
response bias due to the social desirability of a posit-
ive response, especially considering that the survey 
instrument was distributed by members of the 
patients’ treating team. Moreover, the items included 
in the questionnaire could have been further tailored to 
the participants as, for example, knowledge of terms like 
randomisation and study blinding may not have been 
clearly understood.
Conclusion
The current study found that Omani patients and 
their relatives had low level of knowledge of clinical 
trials. However, there was a moderate level of interest 
in participating in such trials, especially when partic- 
ipation was suggested by a treating physician. These 
findings should therefore be considered when devel-
oping initiatives to encourage clinical trial enrolment 
in Oman. Further research on Omani patients’ and 
relatives’ attitudes towards clinical trial participation 
is recommended.
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